Introduction
After Alzheimer's disease (AD), dementia with Lewy bodies (DLB) is a relatively common neurodegenerative dementia, with a high frequency of neuropsychiatric symptoms and extrapyramidal signs. [1] The pathological hallmark of DLB is the presence of cerebral Lewy bodies that contain alpha-synuclein. In addition, up to 50% of DLB-patients have concomitant AD-pathology (amyloid plaques and neurofibrillary tangles). This pathological overlap complicates the differential diagnosis of AD versus DLB. Patients with mixed pathology may be less likely to express core DLB symptoms [2, 3] and abnormal AD-biomarkers (such as cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET)) may lead to a misdiagnosis of AD. Furthermore, DLB patients with mixed pathology seem to have a worse prognosis, and possibly more neuropsychiatric symptoms, such as hallucinations. [2] 123 I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ( 123 I-FP-CIT) single photon emission computed tomography (SPECT) studies have demonstrated reduced striatal dopamine transporter (DAT) binding in DLB and Parkinson's disease (PD)-an in-vivo proxy of nigrostriatal degeneration -but not in AD. 123 I-FP-CIT SPECT has shown good diagnostic accuracy for DLB and is included in the diagnostic criteria as an indicative biomarker. [1] In addition to its high affinity to the DAT, 123 I-FP-CIT binds also with modest affinity to the serotonin transporter (SERT). [4] Serotonin is a neurotransmitter that regulates the neuroendocrine system as well as cognitive functions and mood. Serotonergic deficits have been related to symptoms of depression and psychosis in both DLB and AD. [5] DAT and SERT display a different distribution in subcortical structures, which makes it possible to simultaneously assess the striatal dopaminergic and extrastriatal serotonergic system with one 123 I-FP-CIT SPECT scan. [4] The influence of concomitant AD-pathology on 123 I-FP-CIT binding is still unknown. We aimed to study if concomitant AD-pathology influences 123 I-FP-CIT binding (both striatal DAT and extrastriatal SERT). We compared DAT and SERT binding between DLB with concomitant AD-pathology (DLB/AD+) and 'pure DLB' (DLB/AD-). Based on previously described differences in clinical symptoms [2, 3] we hypothesized that DLB/AD+ patients may have lower SERT binding and DLB/AD-patients may have lower DAT binding. We aimed to relate the findings to motor, cognitive and psychiatric symptoms.
Material and methods

Patient selection
From our memory clinic population, the Amsterdam Dementia Cohort, we selected 55 patients with probable DLB [1] with an available 123 I-FP-CIT SPECT scan, a T 1 -weighted magnetic resonance imaging (MRI) scan and CSF. One patient was excluded due to use of a serotonin reuptake inhibitor (possible interference with 123 I-FP-CIT SERT-binding) and two due to segmentation failures. Fifty-two patients were divided, based on their CSF tau/ a-42 ratio [6] into DLB/AD+ (tau/ a-42 ratio>0.52, n=15) or DLB/AD-(tau/ a-42 ratio0.52 (n=37)). All patients had given written informed consent to use their clinical and imaging data. All patients provided informed consent to enter their clinical and imaging data, obtained as part of routine patient care, in a pseudonymised database for research purposes.
This procedure was approved by the local Medical Ethics Committee.
Clinical data were collected prospectively: Neuropsychiatric symptoms were assessed by the Neuropsychiatric Inventory (NPI). The relevant subscales were delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, apathy, disinhibition, aberrant motor activity, and nighttime behavioral disturbances. Presence of symptoms was defined as a subscale score>0. In addition to the NPI, depression was assessed by the short form of the Geriatric Depression Scale (GDS-S), presence of depressive symptoms was defined as a score>4. Parkinsonism was assessed by a preformatted checklist based on neurological examination including the presence of bradykinesia, hypokinesia, tremor and/or rigidity.
I-FP-CIT SPECT analysis
We performed imaging according to the guidelines of the European Association of Nuclear Medicine: 123 I-FP-CIT was administered intravenously in a dose of approximately 185 MBq (specific activity >185 MBq/nmol; radiochemical purity >99%; produced as DaTSCAN™ at GE Healthcare, Eindhoven, The Netherlands). After 3 hours, static images were obtained for 30 minutes using a dual-head gamma camera (E.Cam; Siemens, Munich, Germany) with a fan-beam collimator. We used Chang's attenuation correction [7] with an attenuation coefficient of 0.15, and then reconstructed and reoriented the scans to the anterior-posterior commissural plane in Statistical Parametric Mapping 12 software (SPM 12; Wellcome Trust Centre for Neuroimaging, London, UK). Table 1 shows the demographic and clinical characteristics of both groups. DLB/AD+ patients (n=15, 28.8%) were older (p = 0.02) than DLB/AD-patients and showed more right hemispheric medial temporal lobe atrophy (p = 0.02). There were no differences in the presence of parkinsonism, depressive or other neuropsychiatric symptoms. We did not find significant differences between DLB/AD+ and DLB/AD-in striatal 123 I-FP-CIT BRs ( Table 2) . DLB/AD+ patients had statistically significant lower 123 I-FP-CIT BRs than DLB/AD-patients for the left amygdala (p=0.002) and the right hippocampus (p=0.036) ( figure 1) . The difference for the left amygdala remained significant after Bonferroni correction (p<0.008). For the other extrastriatal regions, group differences did not reach statistical significance. 
Regions of interest (ROIs
Results
Discussion
This study is the first to explore the influence of concomitant AD pathology in DLB on neurotransmitter systems by studying both striatal and extrastriatal 123 I-FP-CIT binding. The main findings were a lower 123 I-FP-CIT SERT binding in the left amygdala of DLB/AD+-patients compared to DLB/AD-, and a trend towards a lower right hippocampal SERT binding in DLB/AD+. DAT binding was comparable between groups. In the overall sample, motor symptoms correlated negatively with striatal DAT binding as expected. [8] No correlations with neuropsychiatric symptoms were found.
Strikingly, all mean 123 I-FP-CIT binding ratios were lower in the DLB/AD+ group than in the DLB/ADgroup (Table 1) . However, only the difference in the left amygdala reached statistical significance, after Bonferroni correction. The relatively small size of the DLB/AD+ group probably limited the study to detect other group differences. The overall lower BRs in the DLB/AD+ group, albeit not statistically significant, point in the direction of more extensive neurodegeneration, including the dopaminergic and serotonergic system, in mixed pathology, as has been shown by previous neuropathological and MRI research. [9, 10] Since we corrected for ROI volume, the low BRs in DLB/AD+ are unlikely to be caused only by atrophy. Our hypothesis that 'pure DLB' patients would have lower striatal binding than DLB/AD+ could not be confirmed.
Although compromised SERT binding in different brain regions (e.g., midbrain, thalamus and hypothalamus) has been shown in DLB, no consistent 123 I-FP-CIT SERT binding-pattern has been demonstrated. [4, 11] In autopsy and animal studies, low concentrations of serotonin in amygdala and hippocampus, amongst other regions, have been shown in both DLB and AD. Degeneration of the Raphe nucleus even seemed more pronounced in DLB-compared to in AD-patients with a depression. [5] It is a possibility that DLB-pathology drives a major part of the serotonergic degeneration, but there may be a synergistic effect of the concomitant AD-pathology.
Serotonergic deficits may be associated with psychiatric symptoms in neurodegenerative disease. [5] In this study, we could not demonstrate the association between these symptoms and 123 I-FP-CIT SERT binding. Possible explanations can be the relatively low occurrence of neuropsychiatric symptoms in our sample and the small sample size.
This study provides grounds for future studies on the serotonergic system in DLB, and particularly in DLB/AD+, ideally in larger samples with higher prevalence of neuropsychiatric symptoms.. A limitation of this study is that we used a non-selective radiotracer to study SERT, which hampers assessment of SERT binding in the striatum and cortex. Therefore, confirmation of our findings using a selective SERT tracer, such as 11 C-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ( 11 C-DASB), would be of interest. Insights in the role of serotonergic deficits could have implications for symptomatic therapy. Furthermore, although we corrected for atrophy, we cannot exclude that the trend for a lower 123 I-FP-CIT binding in DLB/AD+ in the right hippocampus can be (partly) explained by partial volume effects. Finally, we did not assess parkinsonism with the widely used UPDRS motor score. However, extrapyramidal symptoms were assessed prospectively in a standardized manner in all patients.
In summary, this study provides a first exploration of the influence of mixed DLB and AD pathology on dopaminergic and serotonergic dysfunction, measured by 123 I-FP-CIT SPECT. Our results advocate further research into the clinical significance of serotonergic deficits in DLB, and particularly in patients with concomitant AD-pathology.
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